| 摘要 |
The treatment and/or prophylactic drugs of post-traumatic stress disorder (PTSD) containing compounds (EP<SUB>1 </SUB>agonists), which activate EP<SUB>1 </SUB>receptor that is subtype of prostaglandin E2 receptor, as an active ingredient. EP<SUB>1 </SUB>agonists such as (13E)-(11alpha,15S,17S)-2,5-ethano-6,9-dioxo-11,15-dihydro-17,20-dimethylprosta-13-enoic acid, PGE<SUB>1</SUB>, or PGE<SUB>2</SUB>, etc. are useful for the treatment of post-traumatic stress disorder (PTSD). |
